Astex terminates epigenetics collaboration with GSK

Astex Pharmaceuticals ($ASTX) says it has decided to hand over the epigenetics program SuperGen was partnered on with GlaxoSmithKline ($GSK) following its merger with the biotech company. SuperGen partnered with GSK back in 2009, but the program failed to make the cut during a pipeline review of the companies' combined assets. "The decision to transfer the Climb epigenetic program to GSK was based on our assessment of internal resources and discussions with GSK," said Harren Jhoti, president of Astex. Release

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.